Trials / Completed
CompletedNCT00094328
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
An Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 2 Years – 13 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of muscles and sexual organs .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bicalutamide | oral |
| DRUG | Anastrozole | oral |
Timeline
- Start date
- 2004-11-22
- Primary completion
- 2008-05-22
- Completion
- 2017-12-06
- First posted
- 2004-10-18
- Last updated
- 2018-06-26
- Results posted
- 2009-07-09
Locations
15 sites across 6 countries: United States, Canada, France, India, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT00094328. Inclusion in this directory is not an endorsement.